SLC5A2 and heart failure: The potential differences in HIF-2α signaling between SGLT2 inhibitors and metformin may be clinically relevant, since (in statistical mediation analyses) the erythrocytosis produced by SGLT2 inhibitors is the most powerful predictor of the ability of these drugs to reduce the risk of serious heart failure events in large-scale clinical trials [144, 145].